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Abstract 
Over 1 billion people globally are estimated to be infected with Toxoplasma gondii with severe or 
unknown consequences and no safe and effective therapies are available against congenital or 
persistent chronic infection. We propose that atovaquone and diclazuril synergistically protect 
against fetal-maternal toxoplasmosis. Methods: Programmed pregnant mice were treated with 
atovaquone and diclazuril monotherapy, or combined (atovaquone + diclazuril) therapy and in-
fected with tachyzoites (0, 300, 600) and the course of infection was studied. Results: Infected 
dams with low dose (300) developed moderate toxoplasmosis complications and treatments were 
similarly effective with minor differences between monotherapies. In contrast, major differences 
were observed amongst varied treatments during high-dose (600) infection and severe related- 
toxoplasmosis complications as follows. Dams developed hydrothorax, ascities and excess weight 
gain. Combined therapy (𝑃𝑃 < 0.01) and to a lesser extent diclazuril monotherapy (𝑃𝑃 < 0.05) pro-
tected dams from excess weight, hydrothorax, and ascities. Infected dams exhibited splenomegaly, 
hepatomegaly and severe hepatitis. Combined therapy synergistically normalized pathology (𝑃𝑃 < 
0.001) and to a lesser degree monotherapy (diclazuril 𝑃𝑃 < 0.01, and atovaquone 𝑃𝑃 < 0.05) pro-
tected dams from hepatitis and splemomegaly. Additionally, behavioral response to pain stimuli 
and fetal weight and fetal numbers were significantly preserved in treated dams. Conclusions: 
This is the first report describing combined atovaquone and diclazuril therapy a) to be safe in 
pregnancy, b) to exert novel synergistic effects, and c) to protect dams and their nested fetuses 
against adverse effects of severe toxoplasmosis. 
 
Keywords 
Toxoplasma, Atovaquone, Diclazuril, Synergistic, Protection, Fetal Maternal, Congenital  
Toxoplasmosis, Pregnancy, Gastroenteritis 
 
H. S. Oz 
 
 
922 
1. Introduction 
Over 1 billion people globally are estimated to be infected with Toxoplasma gondii, a widespread cause of 
foodborne disease and congenital toxoplasmosis of which diseases include severe health complications which 
are endemic particularly in rural areas [1]. Toxoplasma is classified as a Category B human infectious pathogen 
by the Center for Disease Control (CDC) and National Institute of Health. Acute toxoplasmosis in immuno-
competent people is typically symptomless or appears as flu syndrome; however, it leads to demise in immuno-
compromised patients [2]. Fetal-maternal transmission results in severe complications for the fetus and neonates 
with potential lifelong adverse consequences [3]-[5]. Congenital toxoplasmosis occurs when the fetus of a sero-
negative woman or animal becomes infected with organism or a clinically quiescent maternal infection reacti-
vates, typically associated with pregnancy immunosuppression [3]. 
Toxoplasmosis can manifest as gastrointestinal complications, spontaneous abortion, intrauterine fetal death, 
preterm delivery, or severe fetal malformations, including ocular, cerebral syndromes, and encephalitis [6]. It is 
considered as the third most common foodborne cause of hospitalization and death in patients [1] [7] although 
frequently misdiagnosed or under-diagnosed [8]. From 1,500,000 predicted cases of toxoplasmosis, only small 
fraction (15%) is clinically detected each year in USA [9]. 
Toxoplasma invades the central nervous system and affects the brain development with pathological as well 
as psycho-behavioral alteration including mental retardation [10]-[12]. Recently, maternal exposure or latent in-
fection has been linked to possible increased risk for autism and schizophrenia, and this theory has received 
considerable scientific and media attention. 
There is no safe and effective (FDA approved) therapy to prevent/eradicate the chronic infection or protect 
against congenital toxoplasmosis. Therefore, identification of new and highly effective therapeutic agents to 
prevent and/or treat toxoplasmosis is required to impact this disease. Current therapy for congenital toxoplasmo-
sis relies primarily on spiramycin associated with pyrimethamine-sulfadoxine combined therapy, with the goal 
of preventing transfer of organism from the actively infected mother to the fetus. However, the adverse effect of 
treatment with these potentially fetotoxic drugs must be considered [13]-[16]. Pyrimethamine is a pregnancy 
category C drug and can cause bone marrow suppression in both mother and inborn. Other treatments have in-
cluded azithromycin, clarithromycin, spiramycin, atovaquone, dapsone, and cotrimoxazole (trimethoprim sul-
famethoxazole) although their efficacy is not proven [17]. Similarly, spiramycin monotherapy can be effective 
only when administered early in pregnancy and used principally as a preventive measure [16]. More than half 
(58%) of the patients received spiramycin retain Toxoplasma DNA in their peripheral blood as they remained 
infected [15]. In France of 257 live births from sera positive women treated with spiramycin and pyrimetha-
mine-sulfadoxine combined treatment, 66 (24%) infants were found to be infected [18]. 
Atovaquone is an FDA approved toxoplasmosis treatment but not for use in congenital toxoplasmosis [13] 
[19]. Atovaquone is an effective drug against opportunistic disease Pneumocystis pneumonia [20], plasmodial 
infections [21], and Babesia microti causative of human babesiosis [22] [23]. 
Another compound, diclazuril, and its related benzeneacetonitriles have long been used in treatment and pre-
vention of poultry and livestock coccidiosis [24] as well as equine protozoal myeloencephalitis (EPM) [25] [26]. 
Diclazuril is known to be a safe compound at therapeutic dose levels [24]-[26]. Diclazuril principally targets 
chloroplast derived chlorophyll a-D1 complex which is only present in apicomplexan and not in mammalian or-
ganelles [27]. 
Recently, we have reported the efficacy of atovaquone and diclazuril monotherapy to protect dams against in-
flammatory and infectious aspects of mild-to-moderate toxoplasmosis [19] [28]. Therapeutic atovaquone and 
diclazuril combined therapy have not previously been reported nor tested in pregnancy or for toxoplasmosis. 
The objectives of this investigation were to evaluate the synergistic efficacy of atovaquone and diclazuril 
combined therapy against the progression of the maternal fetal toxoplasmosis in our pregnancy model. 
2. Materials and Methods 
2.1. Ethics 
This research was conducted according to the guidelines and approved by the Institutional Biosaftey Committee 
(IBC) and the Care and Use of Laboratory Animal Care (IACUC) at University of Kentucky Medical Center. 
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2.2. Toxoplasma gondii Propagation 
Toxoplasma Type II isolates including ME-49 strain are reported predominant in human congenital Toxoplas-
mosis [29]. For this investigation, Toxoplasma organisms from PTG strain (ME-49, ATCC50841) were origi-
nally cloned and propagated by Dr. Daniel Howe of the Maxwell H. Gluck Equine Research Center at the Uni-
versity of Kentucky [19] [28] [30]. Briefly, Tachyzoites were cultured by serial passage in bovine turbinate cells 
and maintained in minimum essential medium (MEMRS, HyClone Labs, Inc.) supplemented with 4% fetal 
clone III (HyClone, Labs, Inc.), Penicillin/streptomycin/fungizone (BioWhittaker, Inc.), and nonessential amino 
acids solution (HyClone, Labs, Inc.). Upon disruption of the host cell monolayer, extracellular tachyzoites were 
harvested and purified from host cell debris by filtration through 3.0 𝜇𝜇m membranes. Tachyzoites were enume-
rated in a hemocytometer and suspended in phosphate buffer saline (PBS) to the appropriate concentrations for 
inoculation. All inoculations were administered intraperitoneally (i.p.) in 100 𝜇𝜇L volume into dams within 1 h of 
harvesting to ensure viability. 
2.3. Murine Fetal Toxoplasmosis Model 
Day 1 programmed pregnant (9 weeks old) CD1 mice were purchased from Charles River Lab Inc., Wilmington, 
MA). Dams were housed individually in microisolator cages in a pathogen free environment and maintained at 
22˚C with a 12:12 hr light-dark cycle at the Maxwell H. Gluck Equine Research Center Laboratory Animal Fa-
cility. Animals were fed irradiated rodent chow and sterilized drinking water ad libitum. After 5 days acclima-
tion, dams were weighed and ear punched for appropriate identification. Dams were treated with regimens and 
on day 8 assigned into 6 - 8 animals per group and injected i.p. with 100 𝜇𝜇L PBS containing 0, 300, or 600 ta-
chyzoites with 0.5 mL insulin syringes. Control dams received 100 𝜇𝜇L sham injection with PBS alone [19]. 
Animals were monitored daily 3 times for distress, pain, physical appearance, and vaginal discharge to detect 
abortion or early delivery [19] [31]. The experiment was terminated on gestation day 16 before possible early or 
premature birth to study the fetal and maternal aspects of the disease. 
2.4. Atovaquone and Diclazuril Treatments 
In order to study safety and efficacy of atovaquone and diclazuril against fetal-maternal toxoplasmosis, animals 
were divided into groups of 18 - 24 animals. Dams received regimens, atovaquone monotherapy, diclazuril mo-
notherapy, atovaquone + diclazuril combined therapy, or sham incorporated into daily diet as indicated in our 
previous publications [19] [28]. The control group received sham treatment (inert talcum powder). Treatments 
were initiated on Day 5 of pregnancy and continued until day 16. On day 8 of pregnancy dams on treatments or 
sham control arms were further divided into 3 subgroups of 6 - 8 animals and were injected each with 0 (PBS), 
300, or 600 tachyzoites and treatments were continued until dams were euthanatized. Pregnant animals volunta-
rily consumed their diets with no significant changes in their appearance, food consumption, or weight loss/gain. 
2.5. Sample Collection 
Animals were euthanatized using CO2 inhalation. Immediately their chests were opened and blood from heart 
collected in microtainers (BD Biosource, Rockville, MD) for hematocrit evaluation. Sera were separated and 
stored frozen at −80˚C. The splenic weight and length were recorded. Heart, liver, and uterus were excised and 
weighed. Colonic contents were removed and colonic length and weigh data measured and flash frozen in liquid 
nitrogen and stored at −80˚C for future studies [32] [33]. Live fetuses were removed from uteri, counted, and 
weighed and their lengths measured using a digital caliper. All aspects of the investigation were performed ac-
cording to the guidelines by Institutional Biosafety Committee (IBC) and IACUC at University of Kentucky 
Medical Center. 
2.6. Histopathological Examination 
A portion of the right lobe from liver tissues of each dam was placed in cassette and fixed with 10% neutral PBS 
formalin. The specimens were dehydrated and embedded in paraffin, and tissue sections of 5 𝜇𝜇m were stained by 
Hematoxylin Eosin (H&E) [19] [34]. Each slide was evaluated under Ziess light microscopy. Hepatic lesions 
were graded on a scale of 0 to 4+ based on degeneration, inflammation, and necrosis as follows. 
(Grade 0)—no detectable lesions, no degeneration, infiltration of inflammatory cells, and normal tissue ap- 
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pearance. 
(Grade 1)—focal infiltration of inflammatory cells in the tissue and hepatocytes degeneration.  
(Grade 2)—mild multifocal infiltration of inflammatory cells, and hepatocytes degeneration. 
(Grade 3)—moderate multifocal infiltration of inflammatory cells and hepatocytes degeneration. 
(Grade 4)—severe diffuse infiltration of inflammatory cells and necrosis. 
2.6.1. Giemsa Staining 
Giemsa is a delicate polychromatic stain that reveals the fine nuclear detail of Toxoplasma organisms. Giemsa 
stain contains methylene blue azure basic (MBAB) dyes combined with eosin acidic dyes. The deparaffinized 
slide sections were stained with the polychromatic Giemsa (40 drops/50 mL distilled water) to stain nuclei of the 
Toxoplasma organisms and to permit differentiation among the cells. Then, the slides were depreciated in 1% 
glacial acetic acid, dehydrated in alcohol and xylene series, and mounted in synthetic resin on slides. 
2.6.2. Immunohistochemical Staining (IHC) 
Anti-Toxoplasma antibody and IHC procedure were kindly provided by Dr. David S. Lindsay at University of 
West Virginal. Briefly, paraffin-embedded sections were cut, deparaffinized with xylene, rehydrated in alcohol 
baths, washed in PBS with 0.1% BSA, quenched endogenous peroxidase activity by incubating in 3% hydrogen 
peroxide in methanol for 30 min, and then blocked with rabbit serum (Dako number 1699), 30 min. The sections 
were incubated with polyclonal Rh anti-Toxoplasma antibody, diluted 1:500 for 90 min, and developed with 
DAB-chromogen (Dako Carpenteria, CA) for about 5 min until signal developed and subsequently counters-
tained with hematoxylin then ammonia treated dehydrate stepwise through alcohol, clear with xylene [28]. 
2.7. Behavioral Test: Assessment of Pain Related Mechanical Allodynia by Testing  
Abdominal Withdrawal Threshold 
Abdominal withdrawal responses to mechanical stimuli were quantified with von Frey monofilaments (Semmes- 
Weinstein Anesthesiometer Kit) according to our previous publications with some modification [19] [28]. 
Briefly, mice were placed into plastic enclosures on the custom-made screen meshed platform. The monofila-
ment range used for this study included 5 different intensities corresponding to (hair diameter) gram force ((4.08) 
1.0 g; (3.61) 0.4 g; (3.22) 0.166 g; (2.83) 0.07; (2.36) 0.02 g forces). Testing for mechanical stimulation was 
performed on the first and the last days of treatment. A single trial consisted of 5 applications of the each fila-
ment used once every 6 seconds to allow dam to cease any response and return to an inactive position. Mean 
values of the percentage of responses of the abdominal withdrawal to each filament (mean withdrawal/5 × 100) 
were used as % scores for this study. This behavioral test reflected basal level for reflex score and any possible 
sensory changes observed in the treated mice. A total of 4 dams were tested per each group.  
2.8. Statistical Analysis 
Results are expressed as mean ± SEM unless otherwise stated. Data were evaluated with ANOVA followed by 
appropriate post hoc test (Tukey compared all pairs) using GraphPad Instat Version 3 for Windows (Graph-Pad 
Software, San Diego, CA). Statistical significance was set at 𝑃𝑃 < 0.05. 
3. Results 
3.1. Drugs’ Safety and Tolerance 
In the initial study, naïve dams were provided diets containing atovaquone, diclazuril, and atovaquone + dicla-
zuril combined therapy, or sham treatment. Dams voluntarily consumed their diets and no adverse effect, such as 
clinical symptoms and changes in body weight gain rate or appearance were detected compared to those re-
ceived sham treatment. 
3.2. Drugs’ Efficacy 
Next dams were divided into groups and received 1) atovaquone monotherapy, 2) diclazuril monotherapy, 3) 
atovaquone + diclazuril combined, or 4) sham treatment. Each group was infected with 0, 300, or 600 tachy-
zoites. Infected dams developed moderate (300) to severe infection (600). Treatments overall were similarly ef-
H. S. Oz 
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fective in groups infected with lower dose (300) as manifested with moderate toxoplasmosis with minor differ-
ences between monotherapies. In contrast, there were major differences amongst groups treated with varied re-
gimens and high dose (600) induced infection. Therefore, here we essentially present data from groups infected 
with the high dose (600) organisms. Sham treated infected dams developed severe toxoplasmosis related in-
flammation, hydrothorax, ascities, anemia (37 ± 2 versus controls 44.5 ± 1.2) and gained excess weight (60%) 
compared to controls. Combined therapy and diclazuril monotherapy protected dams from anemia (41.1 ± 2.4). 
While, most effective, combined therapy (atovaquone + diclazuril, 𝑃𝑃 < 0.01) synergistically eliminated hydro-
thorax and ascites and to a lesser extent diclazuril monotherapy (𝑃𝑃 < 0.05) protected dams from excess patho-
logical weight gain (Figure 1(a)). 
3.3. Pain Related Abdominal Response to Stimuli and Therapies 
Infected dams showed a significant pain related abdominal hypersensitivity (𝑃𝑃 < 0.05) to mechanical stimuli as 
demonstrated with abdominal spasm and withdrawal compared to the uninfected controls. Combined therapy 
was equally effective as atovaquone monotherapy in preserving the normal abdominal response to stimuli in in-
fected treated dams as compared to infected sham treated animals (Figure 1(b)). In contrast diclazuril monothe-
rapy did not significantly improve behavioral response to pain stimuli in infected dams. 
3.4. Splenomegaly 
Infected dams showed severe splenomegaly (X3 Fold) with loss of germinal structure and massive infiltration of 
epithelioid cells with significant increases in weight and length of splenic tissues and combined therapy syner-
gistically normalized these anomalies and protected dams from severe infection (Figure 2(a) and Figure 2(b)). 
3.5. Hepatitis 
The major striking synergistic effect of combined therapy with atovaquone + diclazuril was noted in the manife-
station of hepatic protection compared to the monotherapy. Hepatic tissues became pale in appearance and en-
larged with drastic increases in weight due to severe infection followed by the inflammatory response in sham 
treated dams (normal versus infected 𝑃𝑃 < 0.001) (Figure 3(a)). Combined therapy synergistically preserved he- 
 
 
Figure 1. (a) Percent of excess body weight gain. Infected sham treated dams (Tox) gained excess 
weight (𝑃𝑃 < 0.001) along with inflammation and edema, compared to the uninfected normal controls. 
Combined (atovaquone + diclazuril) therapy synergistically (𝑃𝑃 < 0.01) and to a lesser extent diclazuril 
monotherapy (𝑃𝑃 < 0.05) protected dams from excess weight gain (𝑛𝑛 = 8/group). (b) Percent of pain 
related abdominal response to von Frey mechanical stimuli with 0.166 GM force. Abdominal hyper-
sensitivity significantly increased in infected sham treated dams (Tox) and combined therapy or ato-
vaquone monotherapy was similarly effective and normalized this pain induced behavioral modifica-
tion in dams. In contrast diclazuril monotherapy had no effect on hypersensitivity to von Frey induced 
sensation (𝑛𝑛 = 4/group).                                                                
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Figure 2. Splenic weight (𝑃𝑃 < 0.001 (a)) and length (𝑃𝑃 < 0.01 (b)) increased due to inflammatory re-
sponse. Infected sham treated dams (Tox) and combined therapy (Atov + Dic) synergistically norma-
lized the pathological weight and length increases, while atovaquone or diclazuril monotherapy had a 
partial but significant therapeutic effect on splenic length or weight (n = 8/group).                   
 
 
Figure 3. Hepatic section slides representative stained with H&E from (a) Toxoplasma infected sham 
treated dam with distorted hepatic architecture, infiltration of mononuclear and polymorphonuclear in-
flammatory cells (open arrows), degenerated and necrotic hepatocytes (closed arrows). (b) Toxoplasma 
infected combined atovaquone + diclazuril treated dam with no visible hepatic inflammatory response 
and injury (n = 8/g).                                                                    
 
patic appearance and weight (respectively, sham versus combined therapy 𝑃𝑃 < 0.001 and versus diclazuril 𝑃𝑃 < 
0.01) and microstructural damages (Figure 3(b), Figure 4(a)). Histopathological investigation revealed severe 
hepatitis with multinucleated dysplastic hepatocytes and giant cell transformation, influx of inflammatory and 
plasma cells, and hepatic cells necrosis. Accordingly, combined atovaquone +diclazuril therapy synergistically 
ameliorated hepatic pathological scores superior to monotherapy (respectively, sham versus combined therapy 𝑃𝑃 
< 0.001, versus diclazuril 𝑃𝑃 < 0.01, and versus atovaquone 𝑃𝑃 < 0.05) (Figure 4(b)). 
3.6. Fetal Health 
Uteri weight significantly increased due to inflammatory cells infiltration and edema in infected dams and par- 
tially improved in treated dams which did not reach significant (Table 1). This may be explained due to the in- 
creased number of healthy fetuses. Infected dams carried retarded fetuses (normal versus infected, 𝑃𝑃 < 0.001) 
with sporadic cases of stillbirth or preterm delivery. Combined treatment and atovaquone monotherapy in a sim-
ilar manner and to a lesser degree diclazuril monotherapy (𝑃𝑃 < 0.01) preserved the number of fetuses, fetal 
length, fetal weight and protected nested fetuses from retardation and demise (Figure 5). 
4. Discussion 
The global Toxoplasma infectivity ranges from 10% to over 90% [35] with estimated incidence rate of conge-
nital toxoplasmosis to be 1.5 cases per 1000 live births [36]. Toxoplasmosis, a “common neglected disease of  
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Figure 4. Hepatic weight (a) and hepatic sections stained with H&E scored from 0 (normal) to 4 (most 
severe lesions) for pathological findings (b) from controls (Co) and infected sham treated dams (Tox) 
compared with those with diclazuril (Dic) and atovaquone (Atov) monotherapy or infected combined 
diclazuril + atovaquone (Dic + Atov) therapy. Hepatic weight (a) and pathological score (b) increased 
significantly (𝑃𝑃 < 0.001) due to infiltration of inflammatory cells and combined therapy (𝑃𝑃 < 0.001) 
and diclazuril (𝑃𝑃 < 0.01), respectively, protected the dams from hepatic injuries (n = 8/group).         
 
 
Figure 5. Fetal weight from dams infected with tachyzoites 
and sham treated compared with atovaquone + diclazuril 
combined therapy (n = 8/group).                         
 
Table 1. Synergistic efficacy of atovaquone and diclazuril combined treatment and monotherapy on Toxoplasma infected 
dams.                                                                                                 
Tissues Control Tox Tox + Dic Tox + Atov Tox + Combined 
Hematocrit (%) 44.5 ± 1.2 37 ± 1.4a 41.1 ± 2.4 34.7 ± 3.3a 40.8 ± 1.5 
Uterus weight (g) 11.6 ± 0.5a 13.9 ± 0.7a 11.9 ± 1.9 12.9 ± 1 12.3 ± 1 
Tissues from normal controls (Control), those infected with 600 tachyzoites and treated with sham (Tox), diclazuril monotherapy (Tox + Dic), atova-
quone monotherapy (Tox +Atov), or combined atovaquone and diclazuril treated dams (Tox + Combined). Animals were monitored 3 times/day until 
16 of pregnancy before termination. Number 8/each group. 𝑃𝑃 value a < 0.05. 
 
poverty” (CDC) with higher prevalence, is estimated in socioeconomically disadvantaged populations in the US 
including woman, African American, Hispanic, and Native American [37]. Several clinical investigations indi-
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cate the importance of toxoplasmosis syndromes and the need for safe and effective therapeutics specifically for 
fetal congenital toxoplasmosis. Congenital toxoplasmosis occurs by fetal transplacental transmission of organ-
isms during maternal infection or reactivation of chronic infection. Toxoplasma fetal-maternal transmission was 
first reported in a 3-day-old infant from New York area in 1934 [38] and ever since the worldwide distribution 
and the significance of congenital toxoplasmosis have been well documented [9] [35] [36]. 
Toxoplasmosis can lead to severe consequences and death in immunocompromised patients, fetus, and neo-
nates [1]. In healthy appearing “infected individuals”, symptoms of infection may be subtle and include dimi-
nished IQ and slight adverse behavioral changes [39]. However, significant toxoplasmosis related syndromes 
occur in fetal and neonatal as well as in immunodeficient subjects. The related syndromes include ocular and 
central nervous system toxoplasmosis and possibly autistic and schizophrenia-related complications [10]-[12] as 
infection may involve brain dopamine changes [40] [41]. According to a longitudinal study, women with chron-
ic toxoplasmosis had a higher risk of self-harm [42]. Another cross-sectional study indicated that Toxoplasma 
seropositives demonstrate increased risk of suicidal violence [43]. Present therapies for toxoplasmosis include 
pyrimethamine, sulfasalazine, sulfadiazine, and spiramycin, which are not always effective or have major side 
effects. Pregnant women who seroconvert are generally given spiramycin in order to reduce the risk of transmis-
sion to the fetus. However, patients who receive spiramycin retain Toxoplasma DNA in their peripheral blood 
[15]. In addition, spiramycin is effective only in early pregnancy and not efficacious when organisms have al-
ready penetrated the placenta [16]. 
In a 20-year prospective clinical trial (1985-2005) of infected mothers (666/676) who were treated with spi-
ramycin alone or combined with pyrimethamine-sulfadoxine with live newborn of which, 112 (17%) confirmed 
with congenital toxoplasmosis and 26% later developed chorioretinitis [14]. Likewise, in another report of live 
birth from infected moms treated with both spiramycin and pyrimethamine-sulfadoxine, the transmission rates 
of toxoplasmosis were 7% in the first, 24% the second and 59% in the third trimesters, respectively [18].  
Because of these inadequacies of available treatments, there is urgent need for more effective chemotherapeu-
tic modalities with less toxicity to encounter fetal and congenital toxoplasmosis as well as recurrent Toxoplasma 
related complications. 
In the current investigation we used combined atovaquone and diclazuril in our fetal-maternal toxoplasmosis 
model to demonstrate novel synergistic properties protecting pregnant host and fetus from the adverse effects of 
exposure to Toxoplasma organisms. The combined therapy had superior effects against toxoplasmosis in com-
parison to atovaquone and diclazuril monotherapy.  
Atovaquone (hydroxy-1,4-naphthoquinone) is an FDA approved drug against acute toxoplasmosis and not 
approved for pregnancy (Figure 6(a) molecular structure). Atovaquone has been proven to be effective drug 
against opportunistic disease Pneumocystis pneumonia [20], malarial infections [21], and Babesia microti causa-
tive of human babesiosis [22] [23] [44]. Atovaquone is used as prophylactic against opportunistic diseases in-
cluding toxoplasmosis in HIV/AIDS and immunocompetent patients. Atovaquone has been reported to be tole-
rated better than other available anti-toxoplasmosis therapies and at least as effective [45]. We have shown ato-
vaquone to be effective against some aspects of mild-to-moderate gastrointestinal toxoplasmosis in the preg-
nancy model [19]. 
Another compound, diclazuril [4-chlorophenyl [2,6-dichloro-4-(4,5-dihydro-3H-3,5-dioxo-1,2,4-triazin-2-yl) 
pheny l acetonitrile] is mainly used in food animals’ industry to prevent coccidial infection (Figure 6(b) mole-
cular structure). It is also used to treat clinical cases of protozoan S. neurona induced EPM in horses [24]-[26]. 
 
 
(a)                        (b) 
Figure 6. Molecular structure of atovaquone (a) and diclazuril (b). 
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After oral administration, diclazuril is absorbed with steady-state concentrations in plasma and cerebrospinal 
fluid (CSF) sufficient to interfere with S. neurona proliferation and with 95% inhibition rate [26]. Diclazuril acts 
specifically on Toxoplasma protochlorophyllide with traces of chlorophyll a, and binds to the photosynthetic 
reaction centers [27]. The diclazuril/herbicide-binding site is highly conserved in apicomplexans including Tox-
oplasma and results in a unique chemotherapeutic sensitivity. Therefore, diclazuril binds the chloroplast epi-
topes to interact with the D1 protein of the photosynthetic reaction hub of Toxoplasma organelles, without any 
harmful effect on the host cells. Additionally, diclazuril can downregulate expression of serine/threonine protein 
phosphatase (EtRACK) in merozoites of Eimeria tenella chicken coccidiosis which results in apoptosis [46]. 
EtRACK has about 98% homology with Toxoplasma organisms which demonstrates a predicted mechanism of 
action for diclazuril against toxoplasmosis. Recently, we reported diclazuril dose dependent effect on moderate 
gastrointestinal complications in our pregnancy model [28]. 
In mild-to-moderate infection, diclazuril monotherapy and to a lesser extent atovaquone monotherapy sup-
pressed the Toxoplasma infection [19] [28]. However in severe cases, atovaquone and diclazuril combined ther-
apy was superior to atovaquone or diclazuril monotherapy in synergistically normalizing or ameliorating toxop-
lasmosis symptoms. These included the improvement of pathologic excess weight gain, ascites, hydrothorax, 
and severity of splenomegaly. The major differences were noted when dams became infected with high dose of 
tachyzoites (600) with the manifestation of the hepatic disease. Combined atovaquone and diclazuril exhibited a 
strong synergistic effect (𝑃𝑃 < 0.001) and protected dams from severe inflammatory infection, while diclazuril 
monotherapy (𝑃𝑃 < 0.01) or atovaquone monotherapy (𝑃𝑃 < 0.5) only partially protected dams from inflammatory 
hepatocellular injuries. Additionally, the number of fetuses, fetal length, and weight were significantly preserved 
in combined therapy. This study demonstrated evidence that atovaquone and diclazuril combined therappy ex-
erts significant synergistic effects in normalization or reduction of the severe pathogenesis and clinical symp-
toms in maternal and fetal toxoplasmosis with minimum risk to the dams and fetuses. 
5. Conclusion 
This is the first report to establish proof of the principle that a) atovaquone and diclazuril combined therapy ex-
erts novel synergistic efficacies in infectious and inflammatory disease, b) it is safe in pregnancy, and c) it syn-
ergistically protects dams and their nested fetuses against severe Toxoplasma infection and adverse toxoplasmo-
sis-related inflammatory complications in pregnancy with no detected side effects. These findings warrant future 
trials of the combined atovaquone and diclazuril as novel synergistic prophylactic and therapeutic approach to 
fetal maternal toxoplasmosis. 
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